Entrada Therapeutics Stock Price To Earning

TRDA Stock  USD 11.98  0.04  0.33%   
Entrada Therapeutics fundamentals help investors to digest information that contributes to Entrada Therapeutics' financial success or failures. It also enables traders to predict the movement of Entrada Stock. The fundamental analysis module provides a way to measure Entrada Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Entrada Therapeutics stock.
CashAccounts Payable
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Entrada Therapeutics Company Price To Earning Analysis

Entrada Therapeutics' Price to Earnings ratio is typically used for current valuation of a company and is one of the most popular ratios that investors monitor daily. Holding a low PE stock is less risky because when a company's profitability falls, it is likely that earnings will also go down as well. In other words, if you start from a lower position, your downside risk is limited. There are also some investors who believe that low Price to Earnings ratio reflects the low pricing because a given company is in trouble. On the other hand, a higher PE ratio means that investors are paying more for each unit of profit.

P/E

 = 

Market Value Per Share

Earnings Per Share

More About Price To Earning | All Equity Analysis

Entrada Price To Earning Driver Correlations

Understanding the fundamental principles of building solid financial models for Entrada Therapeutics is extremely important. It helps to project a fair market value of Entrada Stock properly, considering its historical fundamentals such as Price To Earning. Since Entrada Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Entrada Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Entrada Therapeutics' interrelated accounts and indicators.
0.920.92-0.3-0.890.740.660.941.00.930.970.880.88-0.5-0.74-0.61
0.920.88-0.39-0.820.70.440.90.930.90.950.890.77-0.75-0.81-0.78
0.920.88-0.57-0.860.680.391.00.940.990.960.760.75-0.34-0.52-0.43
-0.3-0.39-0.570.160.10.25-0.52-0.38-0.6-0.380.00.110.030.00.03
-0.89-0.82-0.860.16-0.89-0.66-0.87-0.88-0.86-0.9-0.92-0.910.410.520.43
0.740.70.680.1-0.890.480.70.720.660.790.90.93-0.41-0.55-0.48
0.660.440.390.25-0.660.480.440.610.420.490.640.67-0.26-0.44-0.29
0.940.91.0-0.52-0.870.70.440.960.990.970.790.78-0.39-0.57-0.48
1.00.930.94-0.38-0.880.720.610.960.950.980.860.85-0.5-0.73-0.61
0.930.90.99-0.6-0.860.660.420.990.950.960.770.73-0.4-0.56-0.48
0.970.950.96-0.38-0.90.790.490.970.980.960.890.87-0.52-0.72-0.63
0.880.890.760.0-0.920.90.640.790.860.770.890.94-0.69-0.77-0.72
0.880.770.750.11-0.910.930.670.780.850.730.870.94-0.45-0.69-0.57
-0.5-0.75-0.340.030.41-0.41-0.26-0.39-0.5-0.4-0.52-0.69-0.450.840.94
-0.74-0.81-0.520.00.52-0.55-0.44-0.57-0.73-0.56-0.72-0.77-0.690.840.96
-0.61-0.78-0.430.030.43-0.48-0.29-0.48-0.61-0.48-0.63-0.72-0.570.940.96
Click cells to compare fundamentals
Generally speaking, the Price to Earnings ratio gives investors an idea of what the market is willing to pay for the company's current earnings.
Competition

Entrada Retained Earnings

Retained Earnings

(135.81 Million)

At present, Entrada Therapeutics' Retained Earnings are projected to decrease significantly based on the last few years of reporting.
Based on the latest financial disclosure, Entrada Therapeutics has a Price To Earning of 0.0 times. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The price to earning for all United States stocks is 100.0% higher than that of the company.

Entrada Price To Earning Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Entrada Therapeutics' direct or indirect competition against its Price To Earning to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Entrada Therapeutics could also be used in its relative valuation, which is a method of valuing Entrada Therapeutics by comparing valuation metrics of similar companies.
0.0023.135.233.451.91100%
Entrada Therapeutics is currently under evaluation in price to earning category among its peers.

Entrada Therapeutics Current Valuation Drivers

We derive many important indicators used in calculating different scores of Entrada Therapeutics from analyzing Entrada Therapeutics' financial statements. These drivers represent accounts that assess Entrada Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Entrada Therapeutics' important valuation drivers and their relationship over time.
202020212022202320242025 (projected)
Enterprise Value709.4M243.5M403.9M499.4M603.0M585.0M

Entrada Therapeutics ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Entrada Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Entrada Therapeutics' managers, analysts, and investors.
59.6%
Environmental
63.9%
Governance
Social

Entrada Fundamentals

Return On Equity0.16
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-200%-150%-100%-50%0%50%100%
Return On Asset0.0695
Profit Margin0.26 %
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-700%-600%-500%-400%-300%-200%-100%
Operating Margin(1.11) %
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-1,000%-800%-600%-400%-200%
Current Valuation61.76 M
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-60%-50%-40%-30%-20%-10%
Shares Outstanding37.42 M
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-310%5%10%15%20%25%
Shares Owned By Insiders16.95 %
Shares Owned By Institutions82.48 %
Number Of Shares Shorted1.52 M
Price To Book1.06 X
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-100%-80%-60%-40%-20%
Price To Sales2.08 X
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-20%-15%-10%-5%
Revenue210.78 M
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31
Gross Profit95.04 M
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-200,000%-150,000%-100,000%-50,000%0%
EBITDA47.01 M
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-600%-400%-200%0%200%400%600%800%
Net Income65.63 M
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-1,500%-1,000%-500%0%500%1,000%1,500%
Cash And Equivalents244.25 M
Cash Per Share7.81 X
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31500%1,000%1,500%2,000%
Total Debt59.21 M
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-3150%100%150%
Debt To Equity0.12 %
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-3120%40%60%80%100%120%140%
Current Ratio14.05 X
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-310%100%200%300%
Book Value Per Share11.93 X
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-2,500%-2,000%-1,500%-1,000%-500%0%
Cash Flow From Operations(41.56 M)
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-1,000%-500%0%500%
Short Ratio13.45 X
Earnings Per Share1.44 X
Target Price26.93
Number Of Employees177
Beta-0.17
Market Capitalization448.29 M
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-40%-30%-20%-10%
Total Asset526.32 M
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31500%1,000%1,500%2,000%2,500%
Retained Earnings(129.34 M)
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31200%400%600%800%1,000%1,200%
Working Capital210.97 M
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31
Net Asset526.32 M

About Entrada Therapeutics Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Entrada Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Entrada Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Entrada Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Entrada Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Entrada Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Entrada Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Entrada Therapeutics Stock:
Check out Entrada Therapeutics Piotroski F Score and Entrada Therapeutics Altman Z Score analysis.
For information on how to trade Entrada Stock refer to our How to Trade Entrada Stock guide.
You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Entrada Therapeutics. If investors know Entrada will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Entrada Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
1.44
Revenue Per Share
6.074
Quarterly Revenue Growth
(0.55)
Return On Assets
0.0695
Return On Equity
0.1642
The market value of Entrada Therapeutics is measured differently than its book value, which is the value of Entrada that is recorded on the company's balance sheet. Investors also form their own opinion of Entrada Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Entrada Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Entrada Therapeutics' market value can be influenced by many factors that don't directly affect Entrada Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Entrada Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Entrada Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Entrada Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.


 

Discover investing ideas

Utilize additional investing modules

News Freq…Investor S…